What we have 1.5 years after the AD trial is a green light by the EMA to submit an unconditional, EU-wide MAA application (equivalent to an NDA, except with even better odds for approval), opening the door to a multi-billion dollar market for blarcamesine in 2025.
The fact is that they have seen the full data. The fact that you haven't seen the full data is meaningless.
Who should we believe? Anshu2 is not a credible source of reliable and unbiased information. You certainly don’t pass the smell test and reek of special interests. I’ll safely side with the European Medical Association versus your negative opinion on all things Anavex Life Science.